Lupifil-P Mechanism of Action

Pharmacology: Mechanism of Action: Human granulocyte colony stimulating factor (GCSF) is a glycoprotein, which regulates the production and release of neutrophils from the bore marrow. It acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Increase of white blood coil count (leucocytosis) is the predicted consequence of pegfilgrastim administration.
Pegfilgrastim and filgrastim have been shown to have identical mode of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increase in monocytes and/or lymphocytes.
Pharmacokinetics: The peak serum concentration of pegfilgrastim after a single subcutaneous dose of pegfilgrastim occurs at 16 to 120 hours and serum concentrations of pegfilgrastim are maintained during the period of neutropenia after myelosuppressive chemotherapy. The half-life of pegfilgrastim ranges from 15 to 80 hours after subcutaneous injection. Pegfilgrastim appears to be mainly eliminated by neutrophil mediated clearance, which becomes saturated at higher doses. Consistent with a self-regulating clearance mechanism, the serum concentration of pegfilgrastim declines rapidly at the onset of neutrophil recovery. Elimination of pegfilgrastim is nonlinear with respect to dose, serum clearance of pegfilgrastim decreases with increases in dose. The pharmacokinetics of pegfilgrastim is not expected to be affected by renal or hepatic impairment. No gender related differences were observed in the pharmacokinetics of pegfilgrastim, and no differences were observed in the pharmacokinetics of geriatric patients (≥65 years of age) compared with younger patients (<65 years of age). The pharmacokinetics of pegflgrastim in pediatric patients indicates that the mean AUC appears to be similar to that for adult patients with the exception of the youngest age group (0-5 years).